Lowering Fecal Immunochemical Test Positivity Threshold vs Multitarget Stool RNA Testing for Colorectal Cancer Screening.
作者信息
Niedermaier Tobias, Seum Teresa, Hoffmeister Michael, Brenner Hermann
机构信息
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany.
出版信息
JAMA. 2024 Jul 16;332(3):251-252. doi: 10.1001/jama.2024.9289.
Abstract
摘要
相似文献
1
Lowering Fecal Immunochemical Test Positivity Threshold vs Multitarget Stool RNA Testing for Colorectal Cancer Screening.
JAMA. 2024 Jul 16;332(3):251-252. doi: 10.1001/jama.2024.9289.
2
Multitarget Stool RNA Test for Colorectal Cancer Screening.
JAMA. 2023 Nov 14;330(18):1760-1768. doi: 10.1001/jama.2023.22231.
3
Effect of multitarget faecal immunochemical testing on colorectal cancer screening strategies.
Lancet Oncol. 2024 Jun;25(6):e226. doi: 10.1016/S1470-2045(24)00182-7.
4
PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
AJR Am J Roentgenol. 2021 Oct;217(4):817-830. doi: 10.2214/AJR.20.25416. Epub 2021 Mar 11.
5
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2.
6
Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).
Gut Liver. 2014 Mar;8(2):117-30. doi: 10.5009/gnl.2014.8.2.117. Epub 2014 Mar 11.
7
A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial.
Eur J Cancer Prev. 2013 Jul;22(4):299-304. doi: 10.1097/CEJ.0b013e32835b3882.
8
Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort.
Clin Transl Gastroenterol. 2021 May 24;12(5):e00360. doi: 10.14309/ctg.0000000000000360.
9
Making the best use of quantitative fecal immunochemical test results in colorectal cancer screening.
J Intern Med. 2024 Aug;296(2):118-120. doi: 10.1111/joim.13812. Epub 2024 Jun 18.
10
Multitarget stool DNA testing for colorectal-cancer screening.
N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.
引用本文的文献
1
Novel colorectal cancer screening methods - opportunities and challenges.
Nat Rev Clin Oncol. 2025 Jun 6. doi: 10.1038/s41571-025-01037-7.
2
Cell-free DNA blood-based test compared to fecal immunochemical test for colorectal cancer screening.
Cancer Commun (Lond). 2025 Aug;45(8):987-989. doi: 10.1002/cac2.70037. Epub 2025 May 26.
3
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.
Mol Cancer. 2024 Nov 19;23(1):259. doi: 10.1186/s12943-024-02174-w.
4
Next-Generation Multitarget Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening.
JAMA Intern Med. 2025 Jan 1;185(1):110-112. doi: 10.1001/jamainternmed.2024.6149.
5
Letter to the Editor: FIT Sensitivity-A Clinical Perspective.
Br J Biomed Sci. 2024 Jul 26;81:13444. doi: 10.3389/bjbs.2024.13444. eCollection 2024.
Zotero 插件